Rein Therapeutics, Inc. Annual Report - How They Did This Year

I’m putting together a plain-English guide to help you understand how Rein Therapeutics, Inc. (formerly Aileron Therapeutics) performed this year. My goal is to turn complex filing information into something that makes sense, helping you decide if this company fits your investment goals.

1. What does this company do and how did they perform?

Rein Therapeutics is a clinical-stage biotech company. They develop specialized treatments for fibrotic diseases by targeting the underlying biology of the condition. Because they are still in the research phase, they generate no sales revenue and rely entirely on outside funding to pay for their work.

This year was a major transition. They rebranded from Aileron to Rein in 2024 to signal a shift toward their new peptide treatment platform. They also restructured the company and completed a reverse stock split to maintain their listing on the Nasdaq.

2. Financial performance

The company is in a "survival" phase. They reported a loss of about $18.5 million for the year ending December 31, 2024. With no product sales, their research costs far exceed their cash. To manage expenses, they discontinued their LTI-01 program to focus exclusively on LTI-03, a treatment for pulmonary fibrosis. They currently spend between $1.2 million and $1.5 million per month.

3. Major wins and challenges

The company raised approximately $15 million in late 2024 to extend their operations. However, this funding came with two significant trade-offs:

• Dilution: To raise this capital, the company issued a large number of new shares. This increases the total share count, which reduces the percentage of ownership held by existing shareholders.
• Internal Controls: The company reported a "material weakness" in their financial reporting. This indicates that their internal systems for tracking and accounting for money require improvement, which increases the risk of errors in their financial statements.

4. Financial health

As of December 31, 2024, the company held about $12.8 million in cash. Based on their current spending rate, they have enough capital to operate into the second quarter of 2026. Because they cannot support themselves through sales, they must either raise additional capital or secure a strategic partner to continue their work. If they are unable to do so, they may be forced to halt the LTI-03 program, which is the primary asset of the company.

5. Key risks

• "Going Concern" Warning: Management has formally acknowledged that they may not have sufficient cash to fund operations for the next 12 months, signaling a risk that the company could run out of money.
• Clinical Failure: The company’s value is tied to the success of the LTI-03 clinical trial. If the drug fails to prove safe or effective, the company will likely struggle to raise further funds, which would likely cause a significant decline in stock price.
• Accounting Issues: Due to the reported weaknesses in their financial systems, investors should approach their financial statements with a higher degree of caution.

6. Future outlook

The company is entirely focused on the LTI-03 clinical trial, with results expected in late 2025 or early 2026. Their future depends on producing positive data from this trial. Success in these results could provide the leverage needed to find a partner or raise capital without further diluting existing shareholders.

Investor Takeaway: Rein Therapeutics is a high-risk, speculative investment. Because they have no revenue and a limited cash runway, your investment is essentially a bet on the success of their LTI-03 clinical trial. Before deciding, consider whether you are comfortable with the risks of potential dilution, the "going concern" warning, and the uncertainty inherent in clinical-stage biotech development.